Schlusskurs
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
1.682 EUR | -0.36% | +0.12% | -63.43% |
12.06. | Phaxiam: Kapitalerhöhung um zehn Millionen Euro | CF |
15.04. | Phaxiam: Beginn der Studie zur infektiösen Endokarditis | CF |
Zu einer Liste hinzufügen 0 ausgewählt | KGV | Price to Book | PEG | EV / Sales | Marktkap. / EBITDA | Marktkap. / EBIT | Dividendenrendite (Y) | Kap. ($) | |
---|---|---|---|---|---|---|---|---|---|
-0.92x | - | 0.01x | 22.65x | -1.36x | -1.25x | - | 18.51 Mio. | ||
30.55x | 4,196 | 4.37x | 8.02x | 19.53x | 21.43x | -.--% | 123 Mrd. | ||
-237.56x | 7,402 | 2.08x | 10.38x | 136.67x | 185.06x | -.--% | 122 Mrd. | ||
-529.95x | 7,410 | 6.57x | 14.59x | -177.12x | -167.92x | -.--% | 32.18 Mrd. | ||
-41.28x | 1,114 | 0.26x | 3.35x | -9.64x | -8.09x | -.--% | 23.93 Mrd. | ||
-32.47x | 6,306 | 1.16x | 5.33x | -32.77x | -27.15x | -.--% | 21 Mrd. | ||
22.46x | 3,545 | 0.9x | 4.47x | 14.65x | 15.38x | -.--% | 17.38 Mrd. | ||
11.36x | 1,763 | 8.42x | 2.45x | 6.93x | 8.33x | +2,59% | 14.82 Mrd. | ||
-25.94x | - | -3.15x | - | - | - | -.--% | 14.38 Mrd. | ||
-13.77x | -55,878300 | 5.14x | 36x | -16.79x | -16.24x | -.--% | 12.3 Mrd. | ||
70.45x | 9,658 | -0.54x | 6.47x | 79.69x | 103.77x | -.--% | 12.11 Mrd. | ||
27.84x | 4,255 | 0.38x | 4.33x | 16.03x | 16.29x | -.--% | 12.03 Mrd. | ||
-42.27x | 9,586 | 0.71x | 14.85x | -29.24x | -25.71x | -.--% | 9.12 Mrd. | ||
-75.54x | 6,218 | 8.18x | 110.55x | -79.43x | -63.92x | -.--% | 8.94 Mrd. | ||
17.71x | 13,62 | 0.3x | 8.46x | 14.91x | 16.06x | - | 7.51 Mrd. | ||
16.97x | 3,110 | 0.12x | 3.15x | 11.31x | 12.52x | -.--% | 7.5 Mrd. | ||
67.79x | 8,288 | -0.11x | 21.48x | 155.57x | 115.02x | +0,15% | 7.03 Mrd. | ||
-15.68x | 1 156,65 | 0.7x | 19.35x | -18.84x | -18.48x | -.--% | 6.58 Mrd. | ||
Durchschnitt | -41.68x | 74.2 | 1.97x | 17.40x | 5.30x | 9.71x | +0.17% | 25.05 Mrd. | |
Gewichteter Durchschnitt nach Marktkapitalisierung | -95.49x | 21.35 | 2.82x | 11.64x | 31.79x | 47.38x | +0.09% |
- Börse
- Aktien
- A3EJH8 Aktie
- Sektor PHAXIAM Therapeutics S.A.
- Sektorale Bewertungen
MarketScreener is also available in this country: United States.
Switch edition